Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Cash from Investing Activities (2020 - 2025)

Oncology Institute (TOI) has disclosed Cash from Investing Activities for 6 consecutive years, with -$604000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities fell 105.81% year-over-year to -$604000.0, compared with a TTM value of -$3.8 million through Sep 2025, down 106.32%, and an annual FY2024 reading of $46.2 million, down 26.23% over the prior year.
  • Cash from Investing Activities was -$604000.0 for Q3 2025 at Oncology Institute, up from -$1.2 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $24.9 million in Q2 2023 and bottomed at -$87.8 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$1.9 million, with a median of -$607000.0 recorded in 2021.
  • The sharpest move saw Cash from Investing Activities tumbled 9139.89% in 2022, then surged 1936.43% in 2023.
  • Year by year, Cash from Investing Activities stood at -$9.2 million in 2021, then plummeted by 255.93% to -$32.6 million in 2022, then soared by 135.7% to $11.6 million in 2023, then tumbled by 115.09% to -$1.8 million in 2024, then surged by 65.58% to -$604000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for TOI at -$604000.0 in Q3 2025, -$1.2 million in Q2 2025, and -$202000.0 in Q1 2025.